Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach
From Wikipedia, the free encyclopedia
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007),[1] cert denied, 552 U.S. 1159 (2008) was resolved in early 2008 when the Supreme Court of the United States declined to hear the appeal. Their refusal left standing the appellate court decision, which said that patients have no right to "a potentially toxic drug with no proven therapeutic benefit."[1][2]
Quick Facts Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, Court ...
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach | |
---|---|
Court | United States Court of Appeals for the District of Columbia Circuit |
Full case name | Abigail Alliance for Better Access to Developmental Drugs, et al v. Andrew C. von Eschenbach |
Argued | October 21, 2005 |
Reargued | March 1, 2007 |
Decided | August 7, 2007 |
Citation(s) | 495 F.3d 695 |
Case history | |
Prior history | 2004 WL 3777340 (D.D.C. Aug. 30, 2004); 445 F.3d 470 (D.C. Cir. May 2, 2006). |
Subsequent history | Cert. denied, 552 U.S. 1159 (2008). |
Court membership | |
Judge(s) sitting | Douglas H. Ginsburg, David B. Sentelle, Karen L. Henderson, A. Raymond Randolph, Judith Ann Wilson Rogers, David S. Tatel, Merrick B. Garland, Janice Rogers Brown, Thomas B. Griffith, Brett Kavanaugh (en banc) |
Case opinions | |
Majority | Griffith, joined by Sentelle, Henderson, Randolph, Tatel, Garland, Brown, Kavanaugh |
Dissent | Rogers, joined by Ginsburg |
Close